Prasad S. Kulkarni

About

Dr. Prasad Kulkarni (MD, FRCP, FCP) is a clinical pharmacologist with several years experience in new drug development, clinical research, pharmacovigilance, regulatory support and medical advice.

He works at the Serum Institute of India Ltd. Here he has been involved in the successful clinical development of several new vaccines and recombinant proteins.

He has more than 80 publications in journals like the New England Journal of Medicine, Lancet, Lancet Infectious Diseases etc. He has been a faculty to many national and international conferences.

Employment

• Serum Institute of India (India) Executive Director
  2000 - Present

Education

• Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals MBBS
• B. J. Medical College & Sassoon Hospital MD (Clinical Pharmacology)

Projects & Funding

Projects & funding information is unavailable.

Publications (50)

• Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, cont…
  Lancet (London, England) 2025 10 citations DOI: 10.1016/s0140-6736(25)00046-7
  +Save
• Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.
  The Lancet. Infectious diseases 2025 4 citations DOI: 10.1016/s1473-3099(25)00215-4
  +Save
• Proceedings of the dengue endgame summit: Imagining a world with dengue control.
  Vaccine 2024 2 citations DOI: 10.1016/j.vaccine.2024.06.038
  +Save
• The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
  Lancet (London, England) 2024 22 citations DOI: 10.1016/s0140-6736(24)00249-6
  +Save
• Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
  Lancet (London, England) 2024 386 citations DOI: 10.1016/s0140-6736(23)02511-4
  +Save
• Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.
  The Lancet. Infectious diseases 2024 8 citations DOI: 10.1016/s1473-3099(24)00576-0
  +Save
• A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
  Scientific reports 2023 8 citations DOI: 10.1038/s41598-023-43578-w
  +Save
• A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
  Vaccine 2023 8 citations DOI: 10.1016/j.vaccine.2023.07.045
  +Save
• Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
  JAMA pediatrics 2023 12 citations DOI: 10.1001/jamapediatrics.2023.2552
  +Save
• Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.
  The Lancet regional health. Southeast Asia 2023 17 citations DOI: 10.1016/j.lansea.2023.100207
  +Save